Abbott Laboratories (ABT - Free Report) recently announced late-breaking results from the MOMENTUM 3 randomized control clinical trial. Data highlighted the favorable outcome of the HeartMate 3 left ventricular assist device (LVAD) in patients with advanced heart failure.
MOMENTUM 3 data was reviewed across the complete 1028 patient cohort which showed that the device could efficiently extend life-term, improve the quality of life and reduce the incidence of adverse events in such patients.
More on the Study Results
Presented at the American College of Cardiology, the data testified that Abbott’s HeartMate 3 is much superior compared to HeartMate II. The upgraded pump also helped 98.6% patients avoid thrombosis as compared to 86.1%, who used HeartMate II.
Apart from confirming improved survival rates, data showed that complications of stroke, bleeding and the need for surgically removing erroneous pumps can be reduced with the use of the HeartMate 3 pump.
The study also confirms that favorable patient outcome is dependent on the specific design of the pump and not the implant technique.
Market Prospects
Per Allied market research, the global ventricular assist devices market is projected toreach a worth of $1.78 billion by 2023, at a CAGR of 11.8% during the 2017-2023 period.
Abbott is gradually widening the offerings within its Cardiovascular and Neuromodulation arm. However, imminent threat from bigwigs like Medtronic plc (MDT - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Stryker Corporation (SYK - Free Report) is concerning. Meanwhile, the company aims to withstand competitive pressure banking on benefits from technological advantages of certain products.
Other Researches By Abbott
Abbottrecently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT clinical trial, to demonstrate the additional benefits of the company’s mitral valve repair device, MitraClip.
In February 2019, Abbott announced real-world research findings that highlighted the global impact of its FreeStyle Libre flash glucose monitoring system on health outcomes for people affected with diabetes.
In January 2019, Abbott presented study-based data which proved the benefits of BURSTDR spinal cord stimulation for treating chronic pain.
In September 2018, real-world research proved that Abbott’s Portico transcatheter aortic valve was equipped to treat severe aortic stenosis.
In November 2018, Abbott started conducting studies to assess the efficacy of ablation in treating complex cardiac arrythmia patients.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Abbott Laboratories (ABT - Free Report) recently announced late-breaking results from the MOMENTUM 3 randomized control clinical trial. Data highlighted the favorable outcome of the HeartMate 3 left ventricular assist device (LVAD) in patients with advanced heart failure.
MOMENTUM 3 data was reviewed across the complete 1028 patient cohort which showed that the device could efficiently extend life-term, improve the quality of life and reduce the incidence of adverse events in such patients.
More on the Study Results
Presented at the American College of Cardiology, the data testified that Abbott’s HeartMate 3 is much superior compared to HeartMate II. The upgraded pump also helped 98.6% patients avoid thrombosis as compared to 86.1%, who used HeartMate II.
Apart from confirming improved survival rates, data showed that complications of stroke, bleeding and the need for surgically removing erroneous pumps can be reduced with the use of the HeartMate 3 pump.
The study also confirms that favorable patient outcome is dependent on the specific design of the pump and not the implant technique.
Market Prospects
Per Allied market research, the global ventricular assist devices market is projected toreach a worth of $1.78 billion by 2023, at a CAGR of 11.8% during the 2017-2023 period.
Abbott is gradually widening the offerings within its Cardiovascular and Neuromodulation arm. However, imminent threat from bigwigs like Medtronic plc (MDT - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Stryker Corporation (SYK - Free Report) is concerning. Meanwhile, the company aims to withstand competitive pressure banking on benefits from technological advantages of certain products.
Other Researches By Abbott
Abbottrecently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT clinical trial, to demonstrate the additional benefits of the company’s mitral valve repair device, MitraClip.
In February 2019, Abbott announced real-world research findings that highlighted the global impact of its FreeStyle Libre flash glucose monitoring system on health outcomes for people affected with diabetes.
In January 2019, Abbott presented study-based data which proved the benefits of BURSTDR spinal cord stimulation for treating chronic pain.
In September 2018, real-world research proved that Abbott’s Portico transcatheter aortic valve was equipped to treat severe aortic stenosis.
In November 2018, Abbott started conducting studies to assess the efficacy of ablation in treating complex cardiac arrythmia patients.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ABT - FREE
Get the latest research report on BSX - FREE
Get the latest research report on MDT - FREE
Get the latest research report on SYK - FREE